Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 425,882 shares, an increase of 58.8% from the July 15th total of 268,180 shares. Based on an average daily volume of 34,680 shares, the short-interest ratio is presently 12.3 days. Currently, 7.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC boosted its stake in Xilio Therapeutics by 39.6% in the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares in the last quarter. Empery Asset Management LP acquired a new stake in shares of Xilio Therapeutics in the fourth quarter valued at $757,000. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics by 68.3% in the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after buying an additional 139,716 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Xilio Therapeutics in the fourth quarter valued at about $27,000. Finally, State Street Corp raised its holdings in shares of Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after buying an additional 22,500 shares during the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Trading Down 0.9%

Shares of Xilio Therapeutics stock opened at $9.41 on Thursday. The stock has a market capitalization of $61.92 million, a price-to-earnings ratio of -5.74 and a beta of -0.14. The firm’s 50-day moving average price is $9.00 and its two-hundred day moving average price is $8.38. Xilio Therapeutics has a 1-year low of $6.47 and a 1-year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.26. The company had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million. Xilio Therapeutics had a negative net margin of 34.06% and a negative return on equity of 71.99%.

Analyst Upgrades and Downgrades

Several research firms recently commented on XLO. Wall Street Zen downgraded Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.